DK3419978T3 - Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere - Google Patents

Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere Download PDF

Info

Publication number: DK3419978T3
Authority: DK; Denmark
Prior art keywords: pyrazin; pyrazolo; derivatives; jak inhibitors; jak
Prior art date: 2016-02-24

Application number

DK17705705.6T

Other languages

English (en)

Inventor

Matthew Frank Brown

Alpay DERMENCI

Andrew Fensome

Brian Stephen Gerstenberger

Matthew Merrill Hayward

Dafydd Rhys Owen

Stephen Wayne Wright

Li Huang Xing

Xiaojing Yang

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-02-24

Filing date

2017-02-10

Publication date

2020-06-02

2017-02-10 Application filed by Pfizer filed Critical Pfizer

2020-06-02 Application granted granted Critical

2020-06-02 Publication of DK3419978T3 publication Critical patent/DK3419978T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

DK17705705.6T 2016-02-24 2017-02-10 Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere DK3419978T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662299130P	2016-02-24	2016-02-24
PCT/IB2017/050748 WO2017144995A1 (en)	2016-02-24	2017-02-10	Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors

Publications (1)

Publication Number	Publication Date
DK3419978T3 true DK3419978T3 (da)	2020-06-02

Family

ID=58054385

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK17705705.6T DK3419978T3 (da)	2016-02-24	2017-02-10	Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere

Country Status (45)

Country	Link
US (4)	US10144738B2 (da)
EP (2)	EP3419978B1 (da)
JP (1)	JP6505956B2 (da)
KR (1)	KR102128671B1 (da)
CN (1)	CN109071546B (da)
AR (1)	AR107714A1 (da)
AU (1)	AU2017222417B2 (da)
CA (1)	CA2958490C (da)
CL (1)	CL2018002358A1 (da)
CO (1)	CO2018008799A2 (da)
CR (1)	CR20180372A (da)
CU (1)	CU24511B1 (da)
CY (1)	CY1122949T1 (da)
DK (1)	DK3419978T3 (da)
DO (1)	DOP2018000187A (da)
EA (1)	EA035036B1 (da)
EC (1)	ECSP18072109A (da)
ES (1)	ES2794779T3 (da)
GE (1)	GEP20217242B (da)
HK (1)	HK1258157A1 (da)
HR (1)	HRP20200781T1 (da)
HU (1)	HUE049305T2 (da)
IL (1)	IL260923B (da)
LT (1)	LT3419978T (da)
MA (2)	MA52987A (da)
MD (1)	MD3419978T2 (da)
ME (1)	ME03743B (da)
MX (1)	MX2018010236A (da)
MY (1)	MY189118A (da)
NI (1)	NI201800080A (da)
NZ (1)	NZ744349A (da)
PH (1)	PH12018501788A1 (da)
PL (1)	PL3419978T3 (da)
PT (1)	PT3419978T (da)
RS (1)	RS60261B1 (da)
RU (1)	RU2718902C2 (da)
SG (1)	SG11201806307YA (da)
SI (1)	SI3419978T1 (da)
SV (1)	SV2018005726A (da)
TN (1)	TN2018000295A1 (da)
TW (1)	TWI665201B (da)
UA (1)	UA119835C2 (da)
UY (1)	UY37133A (da)
WO (1)	WO2017144995A1 (da)
ZA (1)	ZA201804972B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6505956B2 (ja)	2016-02-24	2019-04-24	ファイザー・インク	ＪＡＫ阻害剤としてのピラゾロ［１，５−ａ］ピラジン−４−イル誘導体
US20190292188A1 (en)	2018-02-27	2019-09-26	Incyte Corporation	Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
CA3090842A1 (en) *	2018-03-12	2019-09-19	Abbvie Inc.	Inhibitors of tyrosine kinase 2 mediated signaling
AU2019270142A1 (en)	2018-05-17	2020-11-12	Bayer Aktiengesellschaft	Substituted dihydropyrazolo pyrazine carboxamide derivatives
WO2019222677A1 (en)	2018-05-18	2019-11-21	Incyte Corporation	Fused pyrimidine derivatives as a2a / a2b inhibitors
AR116592A1 (es)	2018-10-17	2021-05-26	Lilly Co Eli	Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib
TWI829857B (zh)	2019-01-29	2024-01-21	美商英塞特公司	作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶
CA3136468A1 (en) *	2019-04-12	2020-10-15	Primegene (Beijing) Co., Ltd.	Pyrazolopyrazine derived compounds and pharmaceutical compositions used as jak inhibitors
WO2020222773A1 (en)	2019-04-30	2020-11-05	Celgene Corporation	Combination therapies comprising apremilast and tyk2 inhibitors
AU2020347561A1 (en)	2019-09-11	2022-04-14	Pfizer Inc.	Treatment of hidradenitis with JAK inhibitors
WO2021124095A1 (en) *	2019-12-18	2021-06-24	Pfizer Inc.	Treatment of ulcerative colitis with kinase inhibitors
EP4125900A1 (en)	2020-04-04	2023-02-08	Pfizer Inc.	Methods of treating coronavirus disease 2019
EP4132931A1 (en) *	2020-04-08	2023-02-15	Pfizer Inc.	Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof
EP4210684A1 (en) *	2020-09-11	2023-07-19	Pulmosim Therapeutics LLC	Compositions and methods for treating or preventing pulmonary hypertension
CN112592345A (zh) *	2020-12-07	2021-04-02	嘉兴特科罗生物科技有限公司	一种三氮唑并吡嗪类化合物及其用途
EP4284802A1 (en) *	2021-02-01	2023-12-06	Janssen Biotech, Inc.	Small molecule inhibitors of salt inducible kinases
WO2022208315A1 (en)	2021-03-30	2022-10-06	Pfizer Inc.	Methods for treatment of vitiligo
WO2023076161A1 (en)	2021-10-25	2023-05-04	Kymera Therapeutics, Inc.	Tyk2 degraders and uses thereof
WO2023083200A1 (zh) *	2021-11-12	2023-05-19	南京明德新药研发有限公司	吡唑并环化合物及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8895745B2 (en)	2006-12-22	2014-11-25	Astex Therapeutics Limited	Bicyclic heterocyclic compounds as FGFR inhibitors
AR066879A1 (es) *	2007-06-08	2009-09-16	Novartis Ag	Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
CL2008001709A1 (es)	2007-06-13	2008-11-03	Incyte Corp	Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
CA2727032C (en)	2008-06-10	2018-08-14	Abbott Laboratories	Tricyclic compounds
WO2010016005A1 (en)	2008-08-06	2010-02-11	Pfizer Inc.	6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
US8927545B2 (en)	2009-03-30	2015-01-06	Duke University	Inhibiting Eph B-3 kinase
UY33213A (es)	2010-02-18	2011-09-30	Almirall Sa	Derivados de pirazol como inhibidores de jak
CA2796388A1 (en) *	2010-04-14	2011-10-20	Array Biopharma Inc.	5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
EP2397482A1 (en)	2010-06-15	2011-12-21	Almirall, S.A.	Heteroaryl imidazolone derivatives as jak inhibitors
MX2014004473A (es)	2011-10-12	2015-04-14	Array Biopharma Inc	Imidazo [1,2-c] pirimidinas 5,7-substituidas.
WO2013146963A1 (ja) *	2012-03-28	2013-10-03	武田薬品工業株式会社	複素環化合物
AU2013242492B2 (en)	2012-03-28	2016-12-15	Merck Patent Gmbh	Bicyclic pyrazinone derivatives
WO2015017610A1 (en)	2013-07-31	2015-02-05	Gilead Sciences, Inc.	Syk inhibitors
WO2015086693A1 (en)	2013-12-11	2015-06-18	Almirall, S.A.	Pyrazolopyrimidin-2-yl derivatives as jak inhibitors
WO2015166370A1 (en) *	2014-04-28	2015-11-05	Pfizer Inc.	Heteroaromatic compounds and their use as dopamine d1 ligands
WO2016009028A1 (fr)	2014-07-17	2016-01-21	Valeo Systèmes d'Essuyage	Balai plat caréné d'essuie-glace
PL3227297T3 (pl) *	2014-12-05	2021-10-25	Array Biopharma, Inc.	4,6 podstawione-pyrazolo[1,5-a]pirazyny jako inhibitory kinaz janusowych
TW201639845A (zh)	2015-01-29	2016-11-16	和記黃埔醫藥（上海）有限公司	新的雜芳基和雜環化合物、其組成物及方法
WO2016130920A2 (en)	2015-02-13	2016-08-18	Dana-Farber Cancer Institute, Inc.	Lrrk2 inhibitors and methods of making and using the same
GB201504565D0 (en)	2015-03-18	2015-05-06	Takeda Pharmaceutical	Novel compounds
DK3290418T3 (da)	2015-04-29	2019-07-01	Wuxi Fortune Pharmaceutical Co Ltd	Janus Kinase (JAK)-hæmmere
JP6895439B2 (ja)	2015-12-22	2021-06-30	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ＩＲＡＫ４調節因子としてのピラゾロ［１，５ａ］ピリミジン誘導体
JP6505956B2 (ja)	2016-02-24	2019-04-24	ファイザー・インク	ＪＡＫ阻害剤としてのピラゾロ［１，５−ａ］ピラジン−４−イル誘導体
JP7193460B2 (ja)	2016-12-23	2022-12-20	プレキシコンインコーポレーテッド	Ｃｄｋ８調節およびその適応症のための化合物および方法
US11168090B2 (en)	2017-01-18	2021-11-09	Array Biopharma Inc.	Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
CN110785418A (zh)	2017-06-21	2020-02-11	豪夫迈·罗氏有限公司	作为irak4调节剂的异二氢吲哚酮衍生物
WO2019034973A1 (en)	2017-08-14	2019-02-21	Pfizer Inc.	PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES

2017
- 2017-02-10 JP JP2018544300A patent/JP6505956B2/ja active Active
- 2017-02-10 UA UAA201808148A patent/UA119835C2/uk unknown
- 2017-02-10 MA MA052987A patent/MA52987A/fr unknown
- 2017-02-10 EA EA201891463A patent/EA035036B1/ru unknown
- 2017-02-10 GE GEAP201714864A patent/GEP20217242B/en unknown
- 2017-02-10 RS RS20200584A patent/RS60261B1/sr unknown
- 2017-02-10 SI SI201730289T patent/SI3419978T1/sl unknown
- 2017-02-10 RU RU2018130547A patent/RU2718902C2/ru active
- 2017-02-10 CN CN201780013165.4A patent/CN109071546B/zh active Active
- 2017-02-10 NZ NZ744349A patent/NZ744349A/en unknown
- 2017-02-10 WO PCT/IB2017/050748 patent/WO2017144995A1/en active Application Filing
- 2017-02-10 CO CONC2018/0008799A patent/CO2018008799A2/es unknown
- 2017-02-10 EP EP17705705.6A patent/EP3419978B1/en active Active
- 2017-02-10 MA MA43668A patent/MA43668B1/fr unknown
- 2017-02-10 ES ES17705705T patent/ES2794779T3/es active Active
- 2017-02-10 HU HUE17705705A patent/HUE049305T2/hu unknown
- 2017-02-10 ME MEP-2020-97A patent/ME03743B/me unknown
- 2017-02-10 PL PL17705705T patent/PL3419978T3/pl unknown
- 2017-02-10 CR CR20180372A patent/CR20180372A/es unknown
- 2017-02-10 EP EP20168877.7A patent/EP3712153B1/en active Active
- 2017-02-10 SG SG11201806307YA patent/SG11201806307YA/en unknown
- 2017-02-10 MX MX2018010236A patent/MX2018010236A/es unknown
- 2017-02-10 MD MDE20190031T patent/MD3419978T2/ro unknown
- 2017-02-10 DK DK17705705.6T patent/DK3419978T3/da active
- 2017-02-10 KR KR1020187024431A patent/KR102128671B1/ko active IP Right Grant
- 2017-02-10 AU AU2017222417A patent/AU2017222417B2/en active Active
- 2017-02-10 PT PT177057056T patent/PT3419978T/pt unknown
- 2017-02-10 TN TNP/2018/000295A patent/TN2018000295A1/en unknown
- 2017-02-10 LT LTEP17705705.6T patent/LT3419978T/lt unknown
- 2017-02-10 MY MYPI2018702937A patent/MY189118A/en unknown
- 2017-02-10 CU CU2018000078A patent/CU24511B1/es unknown
- 2017-02-21 TW TW106105777A patent/TWI665201B/zh active
- 2017-02-21 CA CA2958490A patent/CA2958490C/en active Active
- 2017-02-21 US US15/437,618 patent/US10144738B2/en active Active
- 2017-02-22 UY UY0001037133A patent/UY37133A/es unknown
- 2017-02-23 AR ARP170100462A patent/AR107714A1/es unknown
2018
- 2018-07-18 SV SV2018005726A patent/SV2018005726A/es unknown
- 2018-07-24 ZA ZA2018/04972A patent/ZA201804972B/en unknown
- 2018-08-01 IL IL260923A patent/IL260923B/en unknown
- 2018-08-03 NI NI201800080A patent/NI201800080A/es unknown
- 2018-08-17 CL CL2018002358A patent/CL2018002358A1/es unknown
- 2018-08-23 PH PH12018501788A patent/PH12018501788A1/en unknown
- 2018-08-24 DO DO2018000187A patent/DOP2018000187A/es unknown
- 2018-09-24 EC ECSENADI201872109A patent/ECSP18072109A/es unknown
- 2018-11-06 US US16/181,596 patent/US10822341B2/en active Active
2019
- 2019-01-14 HK HK19100512.8A patent/HK1258157A1/zh unknown
2020
- 2020-05-13 HR HRP20200781TT patent/HRP20200781T1/hr unknown
- 2020-05-15 CY CY20201100470T patent/CY1122949T1/el unknown
- 2020-09-08 US US17/014,533 patent/US11472809B2/en active Active
2022
- 2022-09-07 US US17/939,375 patent/US20230045252A1/en active Pending

Also Published As

Publication number	Publication date
EP3419978B1 (en)	2020-04-15
AU2017222417A1 (en)	2018-08-02
LT3419978T (lt)	2020-06-10
SG11201806307YA (en)	2018-09-27
CU20180078A7 (es)	2019-02-04
EP3712153A1 (en)	2020-09-23
MD3419978T2 (ro)	2020-07-31
ZA201804972B (en)	2019-06-26
US20200399281A1 (en)	2020-12-24
SI3419978T1 (sl)	2020-08-31
DOP2018000187A (es)	2019-01-31
CL2018002358A1 (es)	2018-11-30
RS60261B1 (sr)	2020-06-30
JP2019510003A (ja)	2019-04-11
US10144738B2 (en)	2018-12-04
CN109071546A (zh)	2018-12-21
CA2958490C (en)	2024-02-27
PT3419978T (pt)	2020-06-01
EP3419978A1 (en)	2019-01-02
AR107714A1 (es)	2018-05-23
CY1122949T1 (el)	2021-10-29
IL260923B (en)	2022-01-01
US11472809B2 (en)	2022-10-18
MY189118A (en)	2022-01-26
CA2958490A1 (en)	2017-08-24
ME03743B (me)	2021-04-20
CN109071546B (zh)	2021-03-02
CO2018008799A2 (es)	2018-09-20
US20190071448A1 (en)	2019-03-07
RU2018130547A (ru)	2020-03-25
HUE049305T2 (hu)	2020-09-28
MX2018010236A (es)	2019-01-14
KR102128671B1 (ko)	2020-06-30
ECSP18072109A (es)	2018-10-31
NZ744349A (en)	2023-06-30
WO2017144995A1 (en)	2017-08-31
EA201891463A1 (ru)	2019-03-29
BR112018015501A2 (pt)	2018-12-18
CR20180372A (es)	2018-09-19
HRP20200781T1 (hr)	2020-07-24
GEP20217242B (en)	2021-04-12
PH12018501788A1 (en)	2019-06-17
TN2018000295A1 (en)	2020-01-16
RU2718902C2 (ru)	2020-04-15
MA43668B1 (fr)	2020-05-29
ES2794779T3 (es)	2020-11-19
SV2018005726A (es)	2018-10-24
US20230045252A1 (en)	2023-02-09
NI201800080A (es)	2018-11-22
MA52987A (fr)	2021-04-28
PL3419978T3 (pl)	2020-11-30
AU2017222417B2 (en)	2020-07-09
UY37133A (es)	2017-09-29
CU24511B1 (es)	2021-05-12
US10822341B2 (en)	2020-11-03
EA035036B1 (ru)	2020-04-20
EP3712153B1 (en)	2021-12-01
US20170240552A1 (en)	2017-08-24
RU2018130547A3 (da)	2020-03-25
TWI665201B (zh)	2019-07-11
UA119835C2 (uk)	2019-08-12
KR20180103158A (ko)	2018-09-18
JP6505956B2 (ja)	2019-04-24
HK1258157A1 (zh)	2019-11-08
TW201741313A (zh)	2017-12-01

Publication	Publication Date	Title
DK3419978T3 (da)	2020-06-02	Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere
DK3523301T3 (da)	2020-08-03	Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
DK3523302T3 (da)	2022-08-01	Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
DK3322706T3 (da)	2021-02-01	Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
DK3478682T3 (da)	2021-09-13	[1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser
IL254224A0 (en)	2017-10-31	7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
IL261231B (en)	2021-10-31	Mcl-1 (r)-4-methyl-3,4-dihydropyrazino[1,2-a]indol-1(2h)-one inhibitors
IL266305B (en)	2021-10-31	History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
DK3227297T3 (da)	2021-04-06	4,6-substitueret-pyrazolo[1,5-a]pyraziner som janus kinase-inhibitorer
IL247947B (en)	2019-03-31	7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrazine compounds and 8,7,6,5-tetrahydro-h4-pyrazolo[5,1-a][4,1]diazepine compounds as ros1 inhibitors
DK3478681T3 (da)	2020-03-23	1h-pyrazolo[4,3-b]pyridiner som pde1-inhibitorer
IL247948B (en)	2019-03-31	7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrimidine derivatives and 3,2-dihydro-h1-imidazo[2,1-b]pyrazole derivatives as ros1 inhibitors
IL290419B (en)	2022-10-01	Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
IL262673A (en)	2018-12-31	Pyrazolo[1,5-a]pyrimidine compound
DK3679042T3 (da)	2023-05-01	Imidazo[1,5-A]pyrazin-derivater som PI3Kdelta-inhibitorer
HK1254651A1 (zh)	2019-07-26	吡唑並[1，5-a]嘧啶-3-甲酰胺的環醚衍生物
DK3194408T3 (da)	2019-07-15	Tetrahydropyrrolo[3,4-d][1,3]thiazin-derivat som bace-inhibitor
TH1601001194A (th)	2017-10-19	อนุพันธ์ไตรอะโซโล[4,5-d]ไพริมิดีน ใหม่